ABSTRACT
Advanced glycation end products (AGE) and angiotensin II were closely correlated with the progression of diabetic nephopathy (DN). Nitric oxide (NO) is a protective mediator of renal tubular hypertrophy in DN. Here, we examined the molecular mechanisms of angiotensin-converting enzyme inhibitor (ACEI) and NO signaling responsible for diminishing AGE-induced renal tubular hypertrophy. In human renal proximal tubular cells, AGE decreased NO production, inducible NOS activity, guanosine 3',5'-cyclic monophosphate (cGMP) synthesis, and cGMP-dependent protein kinase (PKG) activation. All theses effects of AGE were reversed by treatment with ACEIs (captopril and enalapril), the NO donor S-nitroso-N-acetylpenicillamine (SNAP), and the PKG activator 8-para-chlorophenylthio-cGMPs (8-pCPT-cGMPs). In addition, AGE-enhanced activation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) were clearly reduced by captopril, enalapril, SNAP, and 8-pCPT-cGMPs. The abilities of ACEIs and NO/PKG activation to inhibit AGE-induced hypertrophic growth were verified by the observation that captopril, enalapril, SNAP, and 8-pCPT-cGMPs decreased protein levels of fibronectin, p21 Waf1/Cip1 , and receptor for AGE. The results of the present study suggest that ACEIs significantly reduced AGE-increased ERK/JNK/p38 MAPK activation and renal tubular hypertrophy partly through enhancement of the NO/PKG pathway.
Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Glycation End Products, Advanced/metabolism , Kidney Tubules, Proximal/drug effects , Kidney Tubules, Proximal/metabolism , Nitric Oxide/metabolism , Captopril/pharmacology , Cell Enlargement/drug effects , Cell Line , Cyclic GMP/analogs & derivatives , Cyclic GMP/pharmacology , Cyclic GMP-Dependent Protein Kinases/metabolism , Enalapril/pharmacology , Enzyme Activation/drug effects , Glycation End Products, Advanced/toxicity , Humans , Hypertrophy/prevention & control , Kidney Tubules, Proximal/pathology , MAP Kinase Signaling System/drug effects , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase Type II/metabolism , S-Nitroso-N-Acetylpenicillamine/pharmacology , Signal Transduction/drug effects , Thionucleotides/pharmacologyABSTRACT
BACKGROUND: Osthole has been widely reported to have pharmacological activities such as anti-cancer, anti-inflammation and anti-hyperlipidemic effects. Klotho was identified as an anti-senescence protein in a variety of tissues. Loss of klotho has been associated with chronic kidney disease. However, potential roles and molecular events for osthole and klotho in diabetic nephropathy remain unclear. PURPOSE: In the current study, we undertook to study the effect of osthole on klotho expression in advanced glycation end products (AGE)-cultured human renal proximal tubular cells, and to investigate the molecular mechanisms of osthole and exogenous klotho against AGE-induced renal tubular hypertrophy. METHODS: Cell viability was elucidated by MTT assay. Protein expression was measured by Western blotting. mRNA level was analyzed by real-time PCR. Cellular hypertrophy growth was evaluated by hypertrophy index. Relative cell size was detected by flow cytometry. RESULTS: We found that raising the ambient AGE concentration causes a dose-dependent decrease in klotho synthesis. Osthole significantly increased AGE-inhibited klotho mRNA and protein expression. Osthole and exogenous klotho treatments significantly attenuated AGE-induced Janus kinase 2 (JAK2)-signal transducers and activators of transcription 1 (STAT1) and STAT3 activation. Moreover, protein levels of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 were augmented by osthole and exogenous klotho. The abilities of osthole and exogenous klotho to reverse AGE-induced cellular hypertrophy were verified by the observation that osthole and exogenous klotho inhibited p21Waf1/Cip1/collagen IV/RAGE expression, total protein content, and cell size. CONCLUSION: Consequently, we found that osthole attenuated AGE-induced renal tubular hypertrophy via induction of klotho expression and suppression of the JAK2-STAT1/STAT3 signaling. These results also showed that klotho might be used as a unique molecular target for the treatment of diabetic nephropathy.
Subject(s)
Coumarins/pharmacology , Glucuronidase/metabolism , Glycation End Products, Advanced/metabolism , Hypertrophy/drug therapy , Kidney Tubules/drug effects , Antigens, Neoplasm/metabolism , Cell Cycle/drug effects , Cell Line , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/pathology , Glucuronidase/pharmacology , Glycation End Products, Advanced/toxicity , Humans , Hypertrophy/chemically induced , Hypertrophy/pathology , Janus Kinase 2/metabolism , Kidney Tubules/metabolism , Kidney Tubules/pathology , Klotho Proteins , Mitogen-Activated Protein Kinases/metabolism , STAT3 Transcription Factor/metabolism , Suppressor of Cytokine Signaling Proteins/metabolismABSTRACT
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines recommended the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate (GFR) for the classification of CKD, but its accuracy was limited to North American patients with estimated GFR <60 mL/min per 1.73 m2 body surface area of European (White) or African (Black) descent. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) developed another equation for estimating GFR, derived from a population that included both participants without kidney disease and with CKD. But many ethnicities were inadequately represented. The International Society of Nephrology, Kidney Disease Improving Global Outcomes committee promulgated clinical practice guidelines, which recommended the CKD-EPI equation. Investigators in Asia subsequently assessed the performance of these GFR estimating equations-the Modification of Diet in Renal Disease study equation, the CKD-EPI equation (creatinine only), and the CKD-EPI equations (creatinine and cystatin C). In this review, we summarize the studies performed in Asia on validating or establishing new Asian ethnicity GFR estimating equations. We included both prospective and retrospective studies which used serum markers traceable to reference materials and focused the review of the performance of GFR estimation by comparisons with the GFR estimations obtained from the CKD-EPI equations.
Subject(s)
Asian People , Glomerular Filtration Rate , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/ethnology , Decision Support Techniques , Global Health , Humans , Practice Guidelines as Topic , Renal Insufficiency, Chronic/physiopathology , Reproducibility of ResultsABSTRACT
We have previously demonstrated that KMUP-1, a xanthine-based nitric oxide enhancer, attenuates diabetic glomerulosclerosis, while increasing renal endothelial nitric oxide synthase expression in rats. However, the antifibrotic mechanisms of KMUP1 treatment in diabetic nephropathy in terms of cell biology and transforming growth factor-ß1 (TGFß1) remain unclear. Therefore, the present study involved investigating the effects of KMUP1 on high glucose (HG) or TGFß1induced profibrotic proteins in mouse mesangial (MES13) cells, and the effects of KMUP1 on streptozotocin (STZ)induced diabetic rats. It was identified that KMUP1 (10 µM) attenuated HG (30 mM)induced cell hypertrophy while attenuating TGFß1 gene transcription and bioactivity in MES13 cells. In addition, KMUP1 attenuated TGFß1 (5 ng/ml)induced Smad2/3 phosphorylation while attenuating HG or TGFß1induced collagen IV and fibronectin protein expression. Furthermore, KMUP1 attenuated HGdecreased Suv39h1 and H3K9me3 levels. Finally, KMUP1 attenuated diabetes-induced collagen IV and fibronectin protein expression in STZdiabetic rats at 8 weeks. In conclusion, KMUP1 attenuates HG and TGFß1induced profibrotic proteins in mesangial cells and attenuation of TGFß1induced signaling and attenuation of HGdecreased Suv39h1 expression may be two of the anti-fibrotic mechanisms of KMUP1.
Subject(s)
Fibrosis/metabolism , Glucose/metabolism , Mesangial Cells/metabolism , Piperidines/metabolism , Xanthines/metabolism , Animals , Cell Line , Collagen Type IV/metabolism , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/pathology , Fibronectins/metabolism , Fibrosis/pathology , Histones/metabolism , Mesangial Cells/pathology , Methyltransferases/metabolism , Mice , Signal Transduction/physiology , Smad2 Protein/metabolism , Smad3 Protein/metabolism , Streptozocin/pharmacology , Transforming Growth Factor beta1/metabolismABSTRACT
Suppressor of variegation 3-9 homolog 1 (Suv39h1) is a histone methyltransferase that trimethylates lysine 9 of histone H3 (H3K9me3), which results in gene silencing. A previous study found that H3K9me3 and Suv39h1 were decreased in diabetic mouse vascular smooth muscle cells whereas Suv39h1 overexpression attenuated ischemic myocardial injury. Moreover, high glucose (HG) decreased H3K9me3 and Suv39h1 levels in some cells. Thus, we studied the roles of Suv39h1 in HG-induced effects in MES13 (mouse mesangial) cells. We found that HG, chaetocin (a Suv39h1 inhibitor) and Suv39h1 siRNA decreased Suv39h1 while increasing fibronectin and p21(WAF1) protein levels. HG increased mRNA while chaetocin increased transcription of fibronectin and p21(WAF1)genes. Both HG and chaetocin decreased histone H3K9me3 levels at the promoters of fibronectin and p21(WAF1) genes. Additionally, Suv39h1 overexpression attenuated HG-induced fibronectin and p21(WAF1) mRNA and protein expressions while attenuating HG-induced cell hypertrophy. Suv39h1 overexpression also attenuated HG-suppressed histone H3K9me3 levels at the promoters of fibronectin and p21(WAF1) genes. Moreover, LY294002 or the dominant-negative phosphoinositide 3-kinase (PI3K) mutant (Δp85) attenuated HG-decreased Suv39h1 and HG-induced fibronectin and p21(WAF1) protein expressions. We concluded that HG decreased Suv39h1 via the PI3K pathway in mesangial cells. Inhibition of Suv39h1 increased fibronectin and p21(WAF1) expressions. Moreover, Suv39h1 overexpression attenuated HG-induced fibronectin and p21(WAF1) expressions and cell hypertrophy while attenuating HG-suppressed histone H3K9me3 levels at the promoters of fibronectin and p21(WAF1) genes.
Subject(s)
Cyclin-Dependent Kinase Inhibitor p21/metabolism , Fibronectins/metabolism , Glucose/pharmacology , Mesangial Cells/drug effects , Mesangial Cells/metabolism , Methyltransferases/metabolism , Repressor Proteins/metabolism , Animals , Cell Line , Cyclin-Dependent Kinase Inhibitor p21/genetics , Dose-Response Relationship, Drug , Gene Expression Regulation/drug effects , Histones/chemistry , Histones/metabolism , Lysine/metabolism , Mesangial Cells/cytology , Mice , Phosphatidylinositol 3-Kinases/metabolism , Promoter Regions, Genetic/genetics , Signal Transduction/drug effectsABSTRACT
Areca nut (AN) chewing is associated with chronic kidney disease (CKD). However, the molecular mechanisms of AN-induced CKD are not known. Thus, we studied the effects of arecoline, a major alkaloid of AN, on proximal tubule (LLC-PK1) cells in terms of cytotoxicity, fibrosis, transforming growth factor-ß (TGF-ß) and c-Jun N-terminal kinase (JNK). We found that arecoline dose (0.1-0.5mM) and time (24-72h)-dependently induced cytotoxicity without causing cell death. Arecoline (0.25 mM) also time-dependently (24-72h) increased fibronectin and plasminogen activator inhibitor-1 (PAI1) protein expressions. Arecoline (0.25 mM) time-dependently (24-72h) increased TGF-ß gene transcriptional activity and supernatant levels of active TGF-ß1. Moreover, arecoline (0.25 mM) activated JNK while SP600125 (a JNK inhibitor) attenuated arecoline-induced TGF-ß gene transcriptional activity. SP600125, but not SB431542 (a TGF-ß receptor type I kinase inhibitor), attenuated arecoline-induced fibronectin and PAI1 protein expressions. Finally, tubulointerstitial fibrosis occurred and renal cortical expressions of fibronectin and PAI1 proteins increased in arecoline-fed mice at 24 weeks. We concluded that arecoline induced tubulointerstitial fibrosis in mice while arecoline-induced TGF-ß and pro-fibrotic proteins (fibronectin, PAI1) are dependent on JNK in LLC-PK1 cells.
Subject(s)
Arecoline/toxicity , Fibrosis/chemically induced , Fibrosis/enzymology , JNK Mitogen-Activated Protein Kinases/metabolism , Kidney Tubules, Proximal/drug effects , Kidney Tubules, Proximal/enzymology , Animals , Cell Death/drug effects , Cell Death/physiology , Dose-Response Relationship, Drug , Fibronectins/biosynthesis , Humans , LLC-PK1 Cells , Male , Mice , Mice, Inbred ICR , Plasminogen Activator Inhibitor 1/biosynthesis , SwineABSTRACT
Probucol is considered to be an important agent in promoting anti-oxidative action and protecting against tissue injury. However, little is known about the effects of probucol on the progression of ovarian carcinoma. The aim of this study was to investigate the effects of probucol on cellular proliferation in human ovarian cancer cells (PA-1 and SKOV-3) and explore the anti-proliferative mechanism of probucol in these cells. We found that probucol decreased cell growth in PA-1 and SKOV-3 cells in a dose-dependent manner. Treatment with probucol had no effect on cytotoxicity, the percentages of Annexin V-FITC positive cells and caspase-3 activity when compared with the vehicle group. No significant differences in the protein expression of Bcl-2 and cytochrome c were observed, both of which were markers of cells undergoing apoptosis. The inhibition of cellular proliferation by probucol was caused by G1-phase arrest through regulating proteins associated with cell cycle progression, such as cyclin D1, p21Waf1/Cip1, and p27Kip1. A further study revealed that probucol strongly impaired the phosphorylation of IκBα and the nuclear translocation of NF-κB (p65). It also suppressed the activation of ERK/JNK/p38 MAPK signaling. Moreover, the NF-κB inhibitor (PDTC), the ERK inhibitor (PD98059), the JNK inhibitor (SP600125), and the p38 MAPK inhibitor (SB203580) markedly attenuated the growth of these cells. Our results indicate that probucol induces anti-proliferative effects via blocking of cell cycle progression and inactivation of NF-κB and MAPK pathways in human ovarian cancer cells.
ABSTRACT
Serum vitamin D is bound to vitamin D-binding protein (DBP). We studied the roles of DBP in streptozotocin-diabetic rats and high glucose (HG)-cultured cells. In diabetic rat sera, there was one upregulated (with a lower isoelectric point [pI], phosphorylated at S268, S270, S464 and T269) and one downregulated (with a higher pI, phosphorylated at S454 and S457) DBP. DBP levels with lower pI were increased in diabetic rat kidney and liver. HG (30 mM) increased DBP protein expression in NRK-49F cells and Clone-9 hepatocytes. HG decreased pI of DBP in Clone-9 hepatocytes. Moreover, DBP short hairpin ribonucleic acid attenuated 1,25-(OH)2D3-induced attenuation of HG-induced renin (but not collagen IV and fibronectin) protein expression in NRK-49F cells. Thus, DBP level is increased whereas DBP is phosphorylated in diabetic rat serum. HG increased DBP protein expression in renal fibroblasts and hepatocytes. Moreover, DBP is required for vitamin D-induced attenuation of HG-induced renin in NRK-49F cells.
Subject(s)
Diabetes Mellitus, Experimental/metabolism , Fibroblasts/metabolism , Kidney/metabolism , Vitamin D-Binding Protein/metabolism , Vitamin D/metabolism , Animals , Cell Line , Cells, Cultured , Fibroblasts/drug effects , Glucose/pharmacology , Hepatocytes/drug effects , Hepatocytes/metabolism , Kidney/drug effects , Male , Phosphorylation/drug effects , Rats , Swine , Up-RegulationABSTRACT
Six-transmembrane epithelial antigen of prostate 4 (Steap4)-knockout mice develop hyperglycaemia and inflammation whereas Steap4 overexpression attenuates atherosclerosis in diabetic mice. Thus, we studied the roles of Steap4 in high glucose (HG, 27.5 mM) or S100B (1 µM, a ligand for the receptor for advanced glycation end-product or RAGE)-induced effects in mouse mesangial (MES13) cells. We found that HG-induced Steap4 protein expression was dependent on S100B. HG increased cell membrane, but not cytosolic, Steap4 protein expression. HG increased protein-protein interaction between Steap4 and S100B, which was confirmed by mass spectrometry of immunoprecipitated S100B. SP600125, LY294002 and AG490 attenuated S100B-induced Steap4 protein expression or gene transcriptional activity. A mutation in signal transducer and activator of transcription 3 (Stat3) site 2 of the Steap4 promoter constructs resulted in a marked decrease in HG or S100B-induced activation of Steap4 gene transcription. Overexpression of Steap4 attenuates HG or S100B-induced collagen IV, fibronectin and cyclooxygenase 2 protein expression. Overexpression of Steap4 attenuates HG or S100B-induced transforming growth factor-ß (TGF-ß). Moreover, overexpression of Steap4 attenuates S100B-induced signalling. Finally, overexpressing Steap4 attenuated renal expression of fibronectin, S100B, TGF-ß, type IV collagen, p-Akt, p-extracellular signal regulated kinase 1/2 and p-Stat3 in streptozotocin-diabetic mice. Thus, overexpression of Steap4 attenuated HG or S100B-induced effects in MES13 cells and attenuated some of S100B-induced effects in diabetic mouse kidneys.
Subject(s)
Glucose/pharmacology , Membrane Proteins/metabolism , Mesangial Cells/drug effects , S100 Calcium Binding Protein beta Subunit/pharmacology , Animals , Cell Line , Cell Membrane/drug effects , Cell Membrane/metabolism , Diabetes Mellitus, Experimental/genetics , Diabetes Mellitus, Experimental/metabolism , Dose-Response Relationship, Drug , Extracellular Signal-Regulated MAP Kinases/metabolism , Fibronectins/metabolism , Immunoblotting , JNK Mitogen-Activated Protein Kinases/metabolism , Janus Kinase 2/metabolism , Male , Membrane Proteins/genetics , Mesangial Cells/metabolism , Mice, Inbred ICR , Phosphatidylinositol 3-Kinases/metabolism , Protein Binding/drug effects , Proto-Oncogene Proteins c-akt/metabolism , S100 Calcium Binding Protein beta Subunit/genetics , S100 Calcium Binding Protein beta Subunit/metabolism , STAT3 Transcription Factor/metabolism , Smad Proteins/metabolism , Time Factors , Transcription, Genetic/drug effects , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/metabolismABSTRACT
Cinnamaldehyde is a major and a bioactive compound isolated from the leaves of Cinnamomum osmophloeum kaneh. It possesses anti-diabetic properties in vitro and in vivo and has anti-inflammatory and anti-cancer effects. To explore whether cinnamaldehyde was linked to altered advanced glycation end products (AGE)-mediated diabetic nephropathy, the molecular mechanisms of cinnamaldehyde responsible for inhibition of AGE-reduced nitric oxide (NO) bioactivity in human renal proximal tubular cells were examined. We found that raising the ambient AGE concentration causes a dose-dependent decrease in NO generation. Cinnamaldehyde significantly reverses AGE-inhibited NO generation and induces high levels of cGMP synthesis and PKG activation. Treatments with cinnamaldehyde, the NO donor S-nitroso-N-acetylpenicillamine, and the JAK2 inhibitor AG490 markedly attenuated AGE-inhibited NOS protein levels and NO generation. Moreover, AGE-induced the JAK2-STAT1/STAT3 activation, RAGE/p27(Kip1) /collagen IV protein levels, and cellular hypertrophy were reversed by cinnamaldehyde. The ability of cinnamaldehyde to suppress STAT activation was also verified by the observation that it significantly increased SCOS-3 protein level. These findings indicate for the first time that in the presence of cinnamaldehyde, the suppression of AGE-induced biological responses is probably mediated by inactivating the JAK2-STAT1/STAT3 cascade or activating the NO pathway.
Subject(s)
Acrolein/analogs & derivatives , Glycation End Products, Advanced/pharmacology , Janus Kinase 2/metabolism , Kidney Tubules/metabolism , Nitric Oxide/metabolism , STAT1 Transcription Factor/metabolism , STAT3 Transcription Factor/metabolism , Acrolein/pharmacology , Cell Line , Cell Survival/drug effects , Humans , Kidney Tubules/drug effects , Nitric Oxide Donors/pharmacology , S-Nitroso-N-Acetylpenicillamine/pharmacology , Signal Transduction/drug effectsABSTRACT
The advanced glycation endproduct (AGE)receptor for AGE (RAGE) axis induces transforming growth factorß (TGFß) expression, cell hypertrophy and increases extracellular matrices that are indicated in the pathogenesis of diabetic nephropathy (DN). RAGE binds to numerous ligands besides AGE, including S100B. In the present study, the roles of S100B in high glucoseinduced p21WAF1, extracellular matrices, TGFßl and cell hypertrophy in mouse mesangial (MES13) cells were investigated. High glucose (30 mM) timedependently (2472 h) induced S100B expression. High glucose and exogenous S100B (1 µM) timedependently increased p21WAF1 gene transcription and protein expression, increased type IV collagen and fibronectin protein expression, and TGFß gene transcription and bioactivity. Exogenous S100B also timedependently activated the extracellular regulated kinases (ERK1/2), p38 kinase and cJun Nterminal kinase (JNK) signaling pathways. Exogenous S100Binduced TGFß gene transcription and bioactivity were attenuated by SB203580 (p38 kinase inhibitor) and PD98059 (ERK1/2 inhibitor). Finally, the knockdown of S100B by small interfering RNA (siRNA) attenuated high glucoseinduced TGFß gene transcription and bioactivity, type IV collagen and fibronectin protein expression and p21WAF1 protein expression. Thus, S100B induced TGFß via the ERK1/2 and p38 kinase pathways in mesangial cells. Additionally, high glucoseinduced profibrotic genes (TGFß, type IV collagen and fibronectin) and cell hypertrophyrelated p21WAF1 are dependent on S100B.
Subject(s)
Gene Expression Regulation/drug effects , Glomerular Mesangium/metabolism , Glucose/pharmacology , MAP Kinase Signaling System/drug effects , S100 Calcium Binding Protein beta Subunit/metabolism , Sweetening Agents/pharmacology , Animals , Cell Line , Collagen Type IV/biosynthesis , Collagen Type IV/genetics , Cyclin-Dependent Kinase Inhibitor p21/biosynthesis , Cyclin-Dependent Kinase Inhibitor p21/genetics , Fibronectins/biosynthesis , Fibronectins/genetics , Fibrosis , Glomerular Mesangium/pathology , MAP Kinase Signaling System/genetics , Mice , S100 Calcium Binding Protein beta Subunit/genetics , Transforming Growth Factor beta/biosynthesis , Transforming Growth Factor beta/geneticsABSTRACT
Renal malrotation along the horizontal plane with the long axis of the kidney in the vertical plane can be classified according to an anomalous rotation of the embryologic kidney during ascent. However, renal malrotation along the sagittal plane with the long axis of the kidney in the horizontal plane cannot be explained embryologically and had only been previously reported in one case. Here we report two cases of renal malrotation with the long axis of the kidney in the horizontal plane. Case 1 was a 43-year-old woman with acute pyelonephritis. Right unilateral malrotated kidney was accidentally found in abdominal CT scan and she recovered uneventfully. Case 2 was a 63-year-old diabetic woman with atrial fibrillation, cerebral hemorrhage, sepsis, acute respiratory failure, acute renal failure and right renal infarction. Right unilateral malrotated kidney was accidentally found in abdominal CT scan and she expired within a few days. Thus, these two patients were the 2nd and the 3rd cases of sagittally malrotated kidneys worldwide.
Subject(s)
Kidney/abnormalities , Kidney/diagnostic imaging , Adult , Female , Humans , Middle Aged , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) study or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations may not be accurate for Asians; thus, we developed modified eGFR equations for Taiwanese adults. METHODS: This cross-sectional study compared the Taiwanese eGFR equations, the MDRD study, and the CKD-EPI equations with inulin clearance (Cin). A total of 695 adults including 259 healthy volunteers and 436 CKD patients were recruited. Participants from the Kaohsiung Medical University Hospital were used as the development set (N = 556) to develop the Taiwanese eGFR equations, whereas participants from the National Taiwan University Hospital were used as the validation set (N = 139) for external validation. RESULTS: The Taiwanese eGFR equations were developed by using the extended Bland-Altman plot in the development set. The Taiwanese MDRD equation was 1.309 × MDRD0.912, Taiwanese CKD-EPI was 1.262×CKD-EPI0.914 and Taiwanese four-level CKD-EPI was 1.205 × four-level CKD-EPI0.914. In the validation set, the Taiwanese equations had the lowest bias, the Taiwanese equations and the Japanese CKD-EPI equation had the lowest RMSE, whereas the Taiwanese and the Japanese equations had the best precision and the highest P30 among all equations. However, the Taiwanese MDRD equation had higher concordance correlation than did the Taiwanese CKD-EPI, the Taiwanese four-level CKD-EPI and the Japanese equations. Moreover, only the Taiwanese equations had no proportional bias among all of the equations. Finally, the Taiwanese MDRD equation had the best diagnostic performance in terms of ordinal logistic regression among all of the equations. CONCLUSION: The Taiwanese MDRD equation is better than the MDRD, CKD-EPI, Japanese, Asian, Thai, Taiwanese CKD-EPI, and Taiwanese four-level CKD-EPI equations for Taiwanese adults.
Subject(s)
Glomerular Filtration Rate , Inulin/blood , Kidney/physiopathology , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/epidemiology , Adult , Cross-Sectional Studies , Female , Humans , Japan/epidemiology , Male , Middle Aged , Renal Insufficiency, Chronic/physiopathology , Risk Factors , Taiwan/epidemiologyABSTRACT
Although exogenous klotho attenuates renal fibrosis, it is not known if exogenous klotho attenuates diabetic nephropathy (DN). Thus, we studied the anti-fibrotic mechanisms of klotho in terms of transforming growth factor-ß (TGF-ß) and signaling pathways in high glucose (HG, 30 mM)-cultured renal interstitial fibroblast (NRK-49F) cells. We found that HG increased klotho mRNA and protein expression. HG also activated TGF-ß Smad2/3 signaling and activated extracellular signal-regulated kinase (ERK1/2) and p38 kinase signaling. Exogenous klotho (400 pM) attenuated HG-induced TGF-ß bioactivity, type II TGF-ß receptor (TGF-ßRII) protein expression and TGF-ß Smad2/3 signaling. Klotho also attenuated HG-activated ERK1/2 and p38 kinase. Additionally, klotho and inhibitors of ERK1/2 or p38 kinase attenuated HG-induced fibronectin and cell hypertrophy. Finally, renal tubular expression of klotho decreased in the streptozotin-diabetic rats at 8 weeks. Thus, exogenous klotho attenuates HG-induced profibrotic genes, TGF-ß signaling and cell hypertrophy in NRK-49F cells. Moreover, klotho attenuates HG-induced fibronectin expression and cell hypertrophy via the ERK1/2 and p38 kinase-dependent pathways.
Subject(s)
Fibroblasts/metabolism , Fibronectins/metabolism , Glucose/physiology , Glucuronidase/physiology , MAP Kinase Signaling System , Animals , Cell Line , Collagen/biosynthesis , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/metabolism , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/pathology , Gene Expression , Hypertrophy/metabolism , Kidney Cortex/metabolism , Kidney Cortex/pathology , Klotho Proteins , Male , Protein Serine-Threonine Kinases/metabolism , Rats, Sprague-Dawley , Receptor, Transforming Growth Factor-beta Type II , Receptors, Transforming Growth Factor beta/metabolism , Smad2 Protein/metabolism , Smad3 Protein/metabolism , Transforming Growth Factor beta/physiology , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
Cisplatin-induced acute kidney injury (AKI) is a major concern among clinicians in prescribing cisplatin-based chemotherapy. This study evaluated and compared the ability of urinary biomarkers, including urinary neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, and the urinary albumin to creatinine ratio (ACR) to predict cisplatin-induced AKI. Thirty-three cancer patients receiving cisplatin-based chemotherapy were prospectively studied, including 10 (30%) who developed AKI (the study group). Changes of urinary biomarkers were compared at 4 hours, 8 hours, and 12 hours, and 1 day, 2 days, 3 days, and 4 days after cisplatin intravenous infusions (75mg/m(2)) versus the baseline. There was a significant increase in urinary NGAL levels from 12 hours to 4 days (p<0.05) compared to baseline after cisplatin infusion in the AKI group. The magnitude of these changes over time differed significantly by group (p<0.001). The area under the receiver operating curve describing the relationship between urinary NGAL levels and AKI within 12 hours was 0.865 (95% confidence interval=0.691-1.000). Urinary NGAL levels independently predicted AKI 12 hours after cisplatin (p=0.045) after adjustments for age, gender, body mass index, baseline serum creatinine, and urinary total protein. Urinary NGAL levels may be an early biomarker of AKI in patients receiving cisplatin-based treatment.
Subject(s)
Acute Kidney Injury/chemically induced , Acute Kidney Injury/urine , Acute-Phase Proteins/urine , Albuminuria/urine , Cisplatin/adverse effects , Cystatin C/urine , Lipocalins/urine , Proto-Oncogene Proteins/urine , Acute Kidney Injury/complications , Albuminuria/complications , Creatinine/urine , Female , Humans , Lipocalin-2 , Male , Middle Aged , ROC CurveABSTRACT
Transforming growth factor-ß (TGF-ß) is pivotal in the pathogenesis of diabetic nephropathy. Type 1 TGF-ß receptor (TGF-ßR1) is degraded by Smad7-dependent ubiquitination-proteasomal pathway, which is deubiquitinated by ubiquitin C-terminal hydrolase-L5 (UCHL5). Therefore, we studied the role of UCHL5 in high glucose (27.8mM)-induced TGF-ßR1 protein expression in mouse mesangial (MES13) cells. UCHL5 short hairpin RNA (shRNA) was used to knock down UCHL5 while LY294002 and the dominant-negative p85 were used to inhibit phosphatidylinositol-3-kinase (PI3K). We found that high glucose increased phospho-Akt, TGF-ßR1 mRNA and protein expression. High glucose also increased UCHL5 protein expression, which was attenuated by LY294002, the dominant-negative p85 and the dominant-negative CREB. High glucose-induced TGF-ßR1 protein expression and TGF-ßR1 protein deubiquitination were attenuated by UCHL5 shRNA. Additionally, high glucose-induced p21(WAF1), fibronectin protein expression and cell hypertrophy were attenuated by UCHL5 shRNA. However, high glucose-induced TGF-ßR1 mRNA, p27(kip1) protein expression and growth inhibition were not affected by UCHL5 shRNA. Finally, glomerular UCHL5 and TGF-ßR1 protein expression were increased in streptozotocin-diabetic rats at 8weeks. We conclude that PI3K-dependent UCHL5 is required for high glucose-induced TGF-ßR1 protein expression in mesangial cells. UCHL5 is also required for high glucose-induced TGF-ßR1 protein deubiquitination, p21(WAF1) and fibronectin protein expression and cell hypertrophy.
Subject(s)
Carboxypeptidases/metabolism , Glucose/metabolism , Mesangial Cells/cytology , Mesangial Cells/metabolism , Protein Serine-Threonine Kinases/metabolism , Receptors, Transforming Growth Factor beta/metabolism , Animals , Cell Line , Cell Size , Cyclic AMP Response Element-Binding Protein/metabolism , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Diabetes Mellitus, Experimental/metabolism , Fibronectins/metabolism , Kidney Glomerulus/metabolism , Kidney Tubules/metabolism , Male , Mice , Phosphatidylinositol 3-Kinases/metabolism , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptor, Transforming Growth Factor-beta Type I , Ubiquitin ThiolesteraseABSTRACT
Transforming growth factor-ß (TGF-ß) is pivotal in diabetic nephropathy (DN). Angiotensin converting enzyme-2 (ACE2) converts angiotensin II (Ang II) to angiotensin 1-7 (Ang-(1-7)), which binds to Mas. Proximal tubular ACE2 is decreased in DN. ACE2 deficiency exacerbates whereas ACE2 overexpression attenuates DN. Thus, we investigated the mechanism of high glucose-decreased ACE2 in terms of the interaction between TGF-ß and ACE2-Ang-(1-7)-Mas in NRK-52E cells. We found that high glucose increased TGF-ß1. SB431542 attenuated high glucose-inhibited ACE2 and Mas and Ang-(1-7) conversion from Ang II while attenuating high glucose-induced fibronectin. TGF-ß1 also decreased ACE2 and Mas and Ang-(1-7) conversion from Ang II. A779 attenuated Ang-(1-7)-decreased TGF-ß1 and Ang-(1-7)-activated JAK2-STAT3. Moreover, A779, LY294002 and AG490 attenuated Ang-(1-7)-inhibited TGF-ß1. The combination of Ang-(1-7) and Mas attenuated TGF-ß1 (but not high glucose)-induced fibronectin. Thus, high glucose decreases ACE2 via TGF-ßR in NRK-52E cells. Additionally, there is a negative feedback function between TGF-ß and ACE2, and the combined inhibition of TGF-ß and activation of the ACE2-Ang-(1-7)-Mas may be useful for treating diabetic renal fibrosis.
Subject(s)
Angiotensin I/metabolism , Glucose/pharmacology , Peptide Fragments/metabolism , Peptidyl-Dipeptidase A/metabolism , Proto-Oncogene Proteins/metabolism , Receptors, G-Protein-Coupled/metabolism , Signal Transduction/drug effects , Transforming Growth Factor beta/metabolism , Amino Acid Sequence , Angiotensin I/chemistry , Angiotensin II/analogs & derivatives , Angiotensin II/pharmacology , Angiotensin-Converting Enzyme 2 , Animals , Benzamides/pharmacology , Cells, Cultured , Chromones/pharmacology , Dioxoles/pharmacology , Fibronectins/metabolism , Gene Expression Regulation/drug effects , Janus Kinase 2/metabolism , LLC-PK1 Cells , Molecular Sequence Data , Morpholines/pharmacology , Peptide Fragments/chemistry , Peptide Fragments/pharmacology , Phosphatidylinositol 3-Kinases/metabolism , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Mas , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Receptor, Transforming Growth Factor-beta Type I , Receptors, Transforming Growth Factor beta/metabolism , Swine , Transcription, Genetic/drug effects , Transforming Growth Factor beta/genetics , Tyrphostins/pharmacologyABSTRACT
Renal interstitial fibrosis is characterized by increased extracellular matrix (ECM) synthesis. Epithelial-mesenchymal transition (EMT) in kidneys is driven by regulated expression of fibrogenic cytokines such as transforming growth factor-beta (TGF-ß). Yam, or Dioscorea alata (DA) is an important herb in Chinese medicine widely used for the treatment of clinical diabetes mellitus. However, the fibrosis regulatory effect of DA is unclear. Thus, we examined TGF-ß signaling mechanisms against EMT in rat fibroblast cells (NRK-49F). The characterization of DA water-extracts used various methods; after inducing cellular fibrosis in NRK-49F cells by treatment with ß-hydroxybutyrate (ß-HB) (10 mM), we used Western blotting to examine the protein expression in the TGF-ß-related signal protein type I and type II TGF-ß receptors, Smads2 and Smad3 (Smad2/3), pSmad2 and Smad3 (pSmad2/3), Smads4, Smads7, and EMT markers. These markers included E-cadherin, alpha-smooth muscle actin (α-SMA), and matrix metalloproteinase-2 (MMP-2). Bioactive TGF-ß and fibronectin levels in the culture media were determined using ELISA. Expressions of fibronectin and Snail transcription factor, an EMT-regulatory transcription factor, were assessed by immunofluorescence staining. DA extract dose-dependently (50-200 µg/mL) suppressed ß-HB-induced expression of fibronectin in NRK-49F cells concomitantly with the inhibition of Smad2/3, pSmad2/3, and Smad4. By contrast, Smad7 expression was significantly increased. DA extract caused a decrease in α-SMA (α-smooth muscle actin) and MMP-2 levels, and an increase in E-cadherin expression. We propose that DA extract might act as a novel fibrosis antagonist, which acts partly by down regulating the TGF-ß/smad signaling pathway and modulating EMT expression.
Subject(s)
Drugs, Chinese Herbal/therapeutic use , Epithelial-Mesenchymal Transition/drug effects , Kidney Diseases/drug therapy , Kidney Diseases/pathology , Kidney/pathology , Smad Proteins, Receptor-Regulated/metabolism , 3-Hydroxybutyric Acid/metabolism , Animals , Cadherins/metabolism , Cell Line , Cell Survival/drug effects , Fibronectins/metabolism , Fibrosis/drug therapy , Fibrosis/metabolism , Fibrosis/pathology , Kidney/cytology , Kidney/drug effects , Kidney/metabolism , Kidney Diseases/metabolism , Rats , Signal Transduction/drug effects , Snail Family Transcription Factors , Transcription Factors/metabolism , Transforming Growth Factor beta/metabolismABSTRACT
UNLABELLED: Renal fibrosis progresses to end stage of diabetes kidney disease, which causes irreversible progressive proximal tubular injury. In a previous study, 20-hydroxyecdysterone (20-HE), a phytoecdysteroid, attenuated renal injury in diabetes models. However, the fibrosis regulatory role remains to be investigated. METHODS: The proximal tubular epithelial cells (designated as HK-2) were treated for 48 h with TGF-ß1 (5 ng/ml) in different concentrations of 20-HE (0 to 500 nM/ml) in the last 24 h of culture. The extracellular fibronectin was measured by ELISA assay. Western blot and immunofluorescence were used to evaluate the expression of TGF-ß1/Smads transducer (including Smad2/3, 4, and 7), epithelial and mesenchymal markers (e.g. E-cadherin and α-smooth muscle actin) and Snail (transcriptional regulators for EMT). RESULTS: 20-HE reverses TGF-ß1-induced increase in fibronectin (both intracellular and extracellular fibronectin). Simultaneously, 20-HE reverses TGF-ß1-induced down-regulation of Smad7. In addition, 20-HE significantly attenuates TGF-ß1-induced upregulation of Smad2/3 and pSmad2/3, and downregulation of E-Cadherin. Moreover, 20-HE dramatically suppresses TGF-ß1-induced increases in the expression of Snail. CONCLUSION: We propose that 20-HE is a potential fibrosis antagonist for renal proximal tubule cells. 20-HE might act through suppressing post-receptor signaling of TGF-ß1 and restoring tubule epithelial character by blocking the expression of Snail.
Subject(s)
Down-Regulation/drug effects , Ecdysterone/pharmacology , Hypoglycemic Agents/pharmacology , Kidney Tubules, Proximal/drug effects , Protective Agents/pharmacology , Signal Transduction/drug effects , Transforming Growth Factor beta1/metabolism , Biomarkers/metabolism , Cell Line , Diabetic Nephropathies/prevention & control , Ecdysterone/therapeutic use , Epithelial-Mesenchymal Transition/drug effects , Fibronectins/metabolism , Fibrosis , Humans , Hypoglycemic Agents/therapeutic use , Kidney Tubules, Proximal/metabolism , Kidney Tubules, Proximal/pathology , Molecular Targeted Therapy , Osmolar Concentration , Phytosterols/pharmacology , Phytosterols/therapeutic use , Protective Agents/therapeutic use , Smad Proteins/metabolism , Snail Family Transcription Factors , Transcription Factors/metabolism , Transforming Growth Factor beta1/antagonists & inhibitors , Up-Regulation/drug effectsABSTRACT
Cyclin D1 plays significant roles in cell cycle entry and migration. We have documented that both integrin α3ß1 expressions and the number of podocytes were reduced in focal segmental glomerulosclerosis. We wondered whether integrin-extracellular matrix (ECM) interaction was involved in the regulation of cyclin D1 expression, and the possible signaling pathways in mitogen-stimulating podocytes. Cultured podocytes were divided into serum (mitogens/growth factors)-starved and serum-stimulated groups. Reverse transcription polymerase chain reaction was used to detect cyclin D1 mRNA, and Western blot analysis was used to measure protein concentrations of cyclin D1 and extracellular signal-regulated kinase (ERK) activation (p-ERK/ERK). The integrin-ECM interaction was blocked by anti-ß1-integrin monoclonal antibody or RGDS (Arg-Gly-Asp-Ser). The MEK inhibitor, U0126, was used to inhibit ERK activation. The results showed that there was little cyclin D1 protein in serum-starved groups, but it was abundant in serum-stimulated groups. Both cyclin D1 mRNA and protein levels were reduced in serum-stimulated podocytes after blocking integrin-ECM interaction. ERK activation in serum-stimulated podocytes was significantly decreased after blocking integrin-ECM interaction. Cyclin D1 mRNA and protein concentrations in serum-stimulated podocytes were reduced after blocking ERK activation by U0126. We demonstrate that integrin-ECM interaction collaborates with mitogens to activate ERK/mitogen-activated protein kinase pathways which are essential for cyclin D1 expression in podocytes.